Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 8, 2014, 32 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $983.36 to $41,600,000.00.

Highlighted Stocks Traded by Insiders:

Synchronoss Technologies (SNCR) - FREE Research Report

Doran Patrick Joseph, who is EVP & Chief Technology Office at Synchronoss Technologies, sold 131 shares at $46.49 on Oct. 8, 2014. Following this transaction, the EVP & Chief Technology Office owned 21,657 shares meaning that the stake was reduced by 0.6% with the 131-share transaction.

Rosenberger Karen, who is EVP & Chief Financial Officer at Synchronoss Technologies, sold 98 shares at $46.49 on Oct. 8, 2014. Following this transaction, the EVP & Chief Financial Officer owned 36,943 shares meaning that the stake was reduced by 0.26% with the 98-share transaction.

The shares most recently traded at $44.44, down $2.05, or 4.61% since the insider transaction. Historical insider transactions for Synchronoss Technologies go as follows:

  • 4-Week # shares sold: 158
  • 12-Week # shares sold: 2,997
  • 24-Week # shares sold: 6,029

The average volume for Synchronoss Technologies has been 475,700 shares per day over the past 30 days. Synchronoss Technologies has a market cap of $1.8 billion and is part of the technology sector and computer software & services industry. Shares are up 46.03% year-to-date as of the close of trading on Wednesday.

Synchronoss Technologies, Inc. provides cloud solutions and software-based activation for connected devices worldwide. The company has a P/E ratio of 50.6. Currently, there are 7 analysts who rate Synchronoss Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNCR - FREE

TheStreet Quant Ratings rates Synchronoss Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Synchronoss Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Splunk (SPLK) - FREE Research Report

Smith Graham, who is Director at Splunk, sold 5,000 shares at $59.11 on Oct. 8, 2014. Following this transaction, the Director owned 94,126 shares meaning that the stake was reduced by 5.04% with the 5,000-share transaction.

The shares most recently traded at $58.34, down $0.77, or 1.32% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 57,110
  • 12-Week # shares sold: 82,593
  • 24-Week # shares sold: 163,680

The average volume for Splunk has been 2.8 million shares per day over the past 30 days. Splunk has a market cap of $6.9 billion and is part of the technology sector and computer software & services industry. Shares are down 14.66% year-to-date as of the close of trading on Wednesday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence in the United States and internationally. Currently, there are 14 analysts who rate Splunk a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Health Net (HNT) - FREE Research Report

Tough Steven D, who is Pres, Govt Progrms at Health Net, sold 8,000 shares at $46.76 on Oct. 8, 2014. Following this transaction, the Pres, Govt Progrms owned 77,669 shares meaning that the stake was reduced by 9.34% with the 8,000-share transaction.

The shares most recently traded at $46.90, up $0.14, or 0.3% since the insider transaction. Historical insider transactions for Health Net go as follows:

  • 4-Week # shares sold: 91,632
  • 12-Week # shares sold: 117,105
  • 24-Week # shares sold: 117,105

The average volume for Health Net has been 951,300 shares per day over the past 30 days. Health Net has a market cap of $3.6 billion and is part of the health care sector and health services industry. Shares are up 58.58% year-to-date as of the close of trading on Wednesday.

Health Net, Inc. provides managed health care services through health plans and government-sponsored managed care plans in the United States. It operates through Western Region Operations and Government Contracts segments. The company has a P/E ratio of 15.5. Currently, there are 3 analysts who rate Health Net a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HNT - FREE

TheStreet Quant Ratings rates Health Net as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Health Net Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null